These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25222296)

  • 1. Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC.
    Brodie SA; Lombardo C; Li G; Kowalski J; Gandhi K; You S; Khuri FR; Marcus A; Vertino PM; Brandes JC
    PLoS One; 2014; 9(9):e107124. PubMed ID: 25222296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
    Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG; Brock MV; Ribeiro MJ; Ramalingam SS; Owonikoko TK; Khuri FR; Brandes JC
    Clin Cancer Res; 2013 Mar; 19(6):1603-11. PubMed ID: 23386692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer.
    Renaud S; Guerrera F; Seitlinger J; Reeb J; Voegeli AC; Legrain M; Mennecier B; Santelmo N; Falcoz PE; Quoix E; Chenard MP; Weingertner N; Beau-Faller M; Massard G
    Clin Lung Cancer; 2018 Nov; 19(6):e919-e931. PubMed ID: 30217639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Du XL; Parikh RC; Lairson DR; Giordano SH; Cen P
    Med Oncol; 2013 Mar; 30(1):440. PubMed ID: 23307252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
    Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG island shore methylation regulates caveolin-1 expression in breast cancer.
    Rao X; Evans J; Chae H; Pilrose J; Kim S; Yan P; Huang RL; Lai HC; Lin H; Liu Y; Miller D; Rhee JK; Huang YW; Gu F; Gray JW; Huang TM; Nephew KP
    Oncogene; 2013 Sep; 32(38):4519-28. PubMed ID: 23128390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients.
    Lopez A; Harada K; Chen HC; Bhutani MS; Weston B; Lee JH; Maru DM; Chin FW; Rogers JE; Thomas I; Amlashi FG; Blum-Murphy MA; Rice DC; Zhao M; Hofstetter WL; Nguyen Q; Ajani JA
    Medicine (Baltimore); 2020 Feb; 99(9):e19295. PubMed ID: 32118743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.
    Ardizzoni A; Tiseo M; Boni L; Di Maio M; Buffoni L; Belvedere O; Grossi F; D'Alessandro V; de Marinis F; Barbera S; Caroti C; Favaretto A; Cortinovis D; Morrica B; Tixi L; Ceschia T; Parisi S; Ricardi U; Grimaldi A; Loreggian L; Navarria P; Huber RM; Belani C; Brunsvig PF; Scagliotti GV; Scolaro T
    Lung Cancer; 2016 Oct; 100():30-37. PubMed ID: 27597278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.
    Ignatov T; Eggemann H; Costa SD; Roessner A; Kalinski T; Ignatov A
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1457-63. PubMed ID: 24825122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.
    Niu N; Schaid DJ; Abo RP; Kalari K; Fridley BL; Feng Q; Jenkins G; Batzler A; Brisbin AG; Cunningham JM; Li L; Sun Z; Yang P; Wang L
    BMC Cancer; 2012 Sep; 12():422. PubMed ID: 23006423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
    Rigas JR
    Oncologist; 2004; 9 Suppl 2():16-23. PubMed ID: 15161987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Di Lorenzo G; Buonerba C; Rozzi A; Lanzetta G; Necchi A; Giannatempo P; Raggi D; Matsumoto K; Choueiri TK; Mullane S; Niegisch G; Albers P; Lee JL; Kitamura H; Kume H; Bellmunt J
    Clin Genitourin Cancer; 2016 Dec; 14(6):494-498. PubMed ID: 27262369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
    Dalvi MP; Wang L; Zhong R; Kollipara RK; Park H; Bayo J; Yenerall P; Zhou Y; Timmons BC; Rodriguez-Canales J; Behrens C; Mino B; Villalobos P; Parra ER; Suraokar M; Pataer A; Swisher SG; Kalhor N; Bhanu NV; Garcia BA; Heymach JV; Coombes K; Xie Y; Girard L; Gazdar AF; Kittler R; Wistuba II; Minna JD; Martinez ED
    Cell Rep; 2017 May; 19(8):1669-1684. PubMed ID: 28538184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.
    Samimi G; Ring BZ; Ross DT; Seitz RS; Sutherland RL; O'Brien PM; Hacker NF; Huh WK
    Cancer Epidemiol Biomarkers Prev; 2012 Feb; 21(2):273-9. PubMed ID: 22194527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
    Ferriss JS; Kim Y; Duska L; Birrer M; Levine DA; Moskaluk C; Theodorescu D; Lee JK
    PLoS One; 2012; 7(2):e30550. PubMed ID: 22348014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.
    Yang YL; Luo XP; Xian L
    PLoS One; 2014; 9(4):e93997. PubMed ID: 24705847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
    Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
    Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.